Bayer (BAYN) Given a €77.00 Price Target at Goldman Sachs Group
Goldman Sachs Group set a €77.00 ($89.53) target price on Bayer (FRA:BAYN) in a report issued on Wednesday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.
Several other equities research analysts have also recently weighed in on BAYN. Barclays set a €85.00 ($98.84) price target on shares of Bayer and gave the company a buy rating in a research report on Wednesday, April 10th. Sanford C. Bernstein set a €86.00 ($100.00) price target on shares of Bayer and gave the company a buy rating in a research report on Wednesday, March 20th. JPMorgan Chase & Co. set a €70.00 ($81.40) price target on shares of Bayer and gave the company a neutral rating in a research report on Thursday, March 28th. Berenberg Bank set a €67.00 ($77.91) price target on shares of Bayer and gave the company a neutral rating in a research report on Monday, April 1st. Finally, Independent Research set a €52.50 ($61.05) price target on shares of Bayer and gave the company a sell rating in a research report on Friday, March 29th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have given a buy rating to the company’s stock. Bayer presently has a consensus rating of Hold and a consensus price target of €81.80 ($95.12).
Shares of FRA:BAYN traded down €0.07 ($0.08) during trading on Wednesday, reaching €61.47 ($71.48). The company had a trading volume of 3,107,391 shares. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: How to Trade Using Analysts Ratings
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.